Valuation dashboard for Lakefront Biotherapeutics N.V. (LKFT) with P/E 3.85, P/B 0.58, EV/EBITDA 5.16 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Analysis Summary
Trailing-twelve-month margins: gross margin 98.0%, operating margin 36.4%, net margin 46.8%.
At $32.08 (closing price, October 28, 2026), LKFT trades at a P/E of 3.85 and an ROE of 16.88%. Market capitalisation stands at $2.1B.
Balance sheet quality for LKFT: current ratio of 20.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 3.85 |
| Price / Book | 0.58 |
| EV / EBITDA | 5.16 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $47.89 |
| vs Current Price | +49.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LKFT | Lakefront Biotherapeutics N.V. | $2.1B | 3.85 | 0.58 | 16.9% |
| IOVA | Iovance Biotherapeutics, Inc. | $6.7B | 8.83 | -40.5% | |
| SLS | SELLAS Life Sciences Group, Inc. | $2.1B | 15.27 | -35.9% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.3B | 30.83 | 6.60 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| MRNA | Moderna, Inc. | $85.5B | 11.99 | -39.2% | |
| REGN | Regeneron Pharmaceuticals, Inc. | $83.7B | 20.12 | 2.62 | 13.8% |
Price
| Price | $32.08 (closing price, October 28, 2026) |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | BE |
Profitability
| Return on Equity | 16.88% |
| Return on Invested Capital | 11.61% |
| Return on Assets | 14.49% |
| Gross Margin | 98.01% |
| Operating Margin | 36.43% |
| Net Margin | 46.83% |
Related companies: IOVA · SLS · VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX
Explore sector: Healthcare · Biotechnology
More sections of LKFT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks